Brief: Aligos Therapeutics Initiates 12-Week Dosing Cohort In Phase 1B Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
25/07/2022 14:27
July 25 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS INITIATES 12-WEEK DOSING COHORT IN
PHASE 1B
STUDY EVALUATING ITS CLASS II CAPSID ASSEMBLY MODULATOR,
ALG-000184
* ALIGOS THERAPEUTICS INITIATES 12-WEEK DOSING COHORT IN
PHASE 1B
STUDY EVALUATING ITS CLASS II CAPSID ASSEMBLY MODULATOR,
ALG-000184
Source text for Eikon: ID:nGNX1RQL6D
Further company coverage: ALGS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue